48,830
edits
(+IHC) |
|||
Line 45: | Line 45: | ||
**Durvalumab (''Imfinzi'', AstraZeneca). | **Durvalumab (''Imfinzi'', AstraZeneca). | ||
**Avelumab (''Bavencio'', Merck/Pfizer). | **Avelumab (''Bavencio'', Merck/Pfizer). | ||
===Anti-PD-L1 drugs - use=== | ===Anti-PD-L1 drugs - use=== |
edits